gout
Conditions
Interventions
Group A:colchicine 0.5mg qd
Group B:colchicine 0.5mg bid
Group C:celexicob 200mg qd
Sponsors
the affiliated hospital of qingdao university
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. >18 years old; 2. Serum urate >420 umol/L; 3. eGFR>60 ml/min/1.73m^2; 4. Given informed consent. 5. Agree to start febuxostat
Exclusion criteria
Exclusion criteria: 1. Contraindications or intolerance to febuxostat; 2. Patients with severe tophi and chronic gouty arthritis with no remission period, or are experiencing flare. 3. Contraindications to colchicine or celecoxib; 4. Biliary tract diseases: biliary tract malformations, cholelithiasis, acute and chronic cholecystitis, cholangitis; 5. Digestive diseases: constipation, obstruction, digestive ulcer active stage patients; 6. Abnormal thyroid function; 7. eGFR < 60ml/min/1.73m^2 or serum creatinine (Cr) =177umol/L; 8. Patients with severe heart disease, such as decompensated heart failure (NYHA stage III and IV); Unstable angina pectoris; History of myocardial infarction within the past 12 months; 9. Patients with xanthinuria; 10. Rheumatoid arthritis or other arthritis disease; 11. Currently using azathioprine, 6-mercaptopurine, cyclosporine, cyclophosphamide, bisazinamide, sulfamethoxazole, trimethoprim, theophylline, thiazide diuretics, aspirin (more than 325mg/ day) or other salicylic acid drugs, losartan, intravenous colchicine treatment; 12. Patients with secondary gout caused by blood disease, kidney disease or tumor radiotherapy and chemotherapy; 13. Brain disease, abnormal judgment ability; Mental illness can not cooperate; 14. Alcohol or drug abuse; 15. Participants who had participated in other clinical trials within three months before the screening of this trial; 16. Malignant tumor, active tuberculosis; 17. Complicated with other diseases, and researchers believe that affect the efficacy evaluation or poor compliance; 18. Taking glucocorticoid drugs; 19. White blood cell count < 4.0×10^9/L, or platelets < 100×10^9/L, or hemoglobin < 90g/L; 20. For any other reason that the researcher considers it inappropriate to participate in the experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mean number of gout flares between 0 and 6 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| proportion of patients with a flare;time to first flare;proportion of patients with >=1 and >=2 gout flares; | — |
Countries
China
Contacts
Public ContactChanggui Li
the affiliated hospital of qingdao university
Outcome results
None listed